Ask AI
ProCE Banner Activity

Danish COMBI Trial: Addition of Ruxolitinib to Interferon-α2 Therapy in Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Slideset Download
Conference Coverage
Ruxolitinib addition to IFN-α2 showed early activity with a manageable toxicity profile in tx-experienced MPN.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by independent educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen